News and Events

Patients Gain Exclusive Access to Clinical Research as a Care Option

Austin, Texas, Sept. 17, 2019 – Elligo Health Research, a healthcare-enabling research organization, is helping Jack Nathan Health patients gain exclusive access to clinical research as a care option at its Canadian Walmart clinics. Jack Nathan Health operates physician-led medical practices that accommodate clinic appointments, lab services, physiotherapy and chiropractic services, and more.

“We take our commitment to exceptional service and care seriously,” said George Barakat, CEO at Jack Nathan Health. “Partnering with Elligo gives us the opportunity to stay informed of the newest advancements, improve our cutting-edge facilities, and continue to meet our patients’ healthcare challenges.”

This partnership expands Elligo’s Research Ready site network to include healthcare experts and their patients from across Canada who otherwise would not have access to treatments through research as care. Jack Nathan Health patients who qualify for a research study will be given the opportunity to receive treatment through Elligo’s Goes Direct® approach, which connects drug development companies to a diverse pool of patients.

“To date, this is our greatest achievement in our mission to connect research to patients,” said John Potthoff, Ph.D., CEO of Elligo. “We are not only better enabling healthcare research; we are leveraging the strength of a large network to accelerate new products to market and improve treatments worldwide.”

 

About Elligo
Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our novel IntElligo Research Stack™ clinical technology and Goes Direct® approach, we connect more physicians and their patients to research, accelerating the clinical development process. Learn more at elligodirect.com.

About Jack Nathan Health®
Jack Nathan Health® is a privately owned and operated Canadian company—and a proud partner of Walmart Canada—dedicated to improving access to healthcare by partnering with highly-qualified medical professionals and delivering consistent, easy-access, patient-centric quality care in state-of-the-art medical and dental clinics, conveniently located inside Walmart Supercentres, with 70-plus locations across Canada. Clinics are independently owned and operated under license by Jack Nathan Medical Inc., and not affiliated with Walmart. Jack Nathan Health® is a registered trade-mark of Jack Nathan Medical Inc. All representations contained herein are made solely by Jack Nathan Health® or its licensed owner operators, and not independently verified by Walmart. All Walmart trademarks are the property of Wal-Mart Stores, Inc. and are used under license. jacknathanhealth.com

About Walmart Canada
Walmart Canada was established in 1994 and is headquartered in Mississauga, Ontario. Store formats include Walmart Supercentres and Walmart discount stores.

Austin, Texas, July 9, 2019 – Elligo Health Research, a healthcare-enabling research organization, announces its partnership with Austin Cancer Center (ACC), the largest independent oncology group in central Texas. The partnership expands Elligo’s Research Ready network to include its first oncology practice, broadening Elligo’s therapeutic specialization and allowing ACC’s oncologists to offer research as a care option. ACC is currently enrolling patients for studies in breast cancer.

“Partnering with Elligo allows us to bring cutting-edge capabilities to our patients,” said Blayne Rush, MBA, ACC’s CEO. “We’re excited they can remain under our care while benefiting from the innovative treatments available through participation in clinical studies.”

“Bringing the Research Ready network to cancer patients in this area is a milestone achievement in our promise to preserve the trusted patient and physician relationship and unite the best clinical experts with the best research infrastructure,” said John Potthoff, Ph.D., Elligo’s CEO.

Elligo continues to bridge the gap between research and care using its Goes Direct® approach. The company has effectively connected numerous patients and sites to research studies across the industry.

About Elligo
Elligo Health Research accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products. Powered by our novel IntElligo Research Stack™ clinical technology and Goes Direct® approach, we connect the best healthcare experts with the best research technologies and infrastructure, thereby becoming the ultimate healthcare-enabling research organization. While maintaining the integrity of the trusted patient and healthcare physician relationship, we ensure all patients have access to clinical research as a care option by engaging healthcare physicians and their patients who otherwise would not participate in clinical research. We also leverage electronic health records to build local communities of research. Learn more at elligodirect.com.

About Austin Cancer Center
With 11 locations, ACC is a leader in integrated oncology services in the central Texas region. ACC currently offers medical oncology, comprehensive breast care and breast oncology, gynecologic oncology, radiation oncology, neuro oncology and diagnostic and interventional radiology specialties.  ACC delivers effective, value-based care and improves physical and mental outcomes for the patients in our community. ACC has key partnerships with multiple hospital systems in central Texas and provides expert care at Austin CyberKnife.

Austin, Texas, June 20, 2019 – Elligo Health Research, a healthcare-enabling research organization, welcomes Brandon Cormier, Jody Casey, and Faith Holmes, MD, FAAFP, AAHPM, HMDC, to its team. The new team members are focused on supporting the company’s mission to connect more healthcare physicians and their patients to clinical research.

As chief commercial officer, Cormier will use his strength in sales and his industry relationships to support the company’s growth. Cormier has been in the health sciences industry for nearly 20 years, at companies like Syneos Health, Ventana Clinical Research, INC Research, GlaxoSmithKline, and DuPont Pharma.

Casey, Elligo’s new vice president, healthcare partnerships, has 20 years of sales knowledge that helps strengthen Elligo’s network of Research Ready physician practices. Her unique ability to build relationships and her passion for making a community impact helps physicians understand the full value of adding clinical research as a care option to their practice.

As Elligo’s medical director, Holmes is building the company’s communities of research and preparing its Research Ready partners to conduct research. Throughout her career in direct patient care and medical practice management, Holmes has gained perspective and medical knowledge that allows her to build rapport with study teams.

“As we grow, we are relying on the specialized knowledge and skills of our team,” said John Potthoff, PhD, CEO of Elligo. “Our newest members fill very important roles. They’re already making a positive impact in our efforts to prioritize research as a healthcare option.”

 

About Elligo
Elligo Health Research accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products. Powered by our novel IntElligo Research Stack™ clinical technology and Goes Direct® approach, we connect the best healthcare experts with the best research technologies and infrastructure, thereby becoming the ultimate healthcare-enabling research organization. While maintaining the integrity of the trusted patient and healthcare physician relationship, we ensure all patients have access to clinical research as a care option by engaging healthcare physicians and their patients who otherwise would not participate in clinical research. We also leverage electronic health records to build local communities of research. Learn more at elligodirect.com.

Austin, Texas, May 15, 2019 – Elligo Health Research, an integrated research organization (IRO), announces the launch of its innovative IntElligo Research Stack™ clinical technology. This standards-based technology platform, which powers the System of Accelerated Research (SOAR™) model, will be launched this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.

”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” said Jacylyn Bodmer, Elligo’s chief information officer. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”

“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” added Rebecca Kush, Ph.D., Elligo’s chief scientific officer.

In addition, the technology provides real-time management financial management, reports, and analytics across research sites; saves time and preserves data integrity by eliminating transcription; and, achieves true eSource. Furthermore, it creates the opportunity to transform research through the SOAR™ model — expanding patient access and driving efficiency by enabling direct data from source to submission.  

“By uniting our Goes Direct® approach with this technology and infrastructure to support physicians, we are creating the ultimate solution for clinical trial execution,” said John Potthoff, Ph.D., Elligo CEO. “The IntElligo platform will become a primary resource for our study sites, increasing the ability for physicians to provide research as a care option and enabling more patients to benefit.”

About Elligo
Elligo Health Research, an integrated research organization, accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using our novel IntElligo Research Stack™ clinical technology and our Goes Direct® approach. We unite the best clinical experts with the best research infrastructure — creating the ultimate clinical trial solution. By maintaining the integrity of the trusted patient and physician relationship and building global communities of research that leverage electronic health records, we ensure all patients have access to clinical trials as a care option. Learn more at elligodirect.com.

Austin, Texas, May 7, 2019 – Elligo Health Research, an integrated research organization (IRO), announced today $20 million in Series C funding led by Piper Jaffray Merchant Banking, a division of Piper Jaffray, with participation from all lead Series A and B investors. This funding is the second investment the company has gained in a little over a year for its innovative and successful approach. In March 2018, Elligo announced $16 million in Series B funding.

“We believe in Elligo’s mission to help all patients have the best access to clinical trials as a care option,” said Tom Schnettler, managing director at Piper Jaffray Merchant Banking and a new Elligo board member. “With more than 62 active research sites, their model has proven itself as the ultimate solution for enhanced patient access and engagement, and that is something we are excited to support.”

“The goal is to drive clinical trial efficiency through innovation,” said John Potthoff, PhD, CEO of Elligo. “Our investors’ continued support in our unique Goes Direct® approach and novel IntElligo Research Stack™ clinical technology has allowed us to quickly expand the base of physicians and their patients who otherwise would not participate in clinical trials.”

“We are proud to renew our investment in Elligo,” said John Crumpler, general partner at Hatteras Venture Partners. “Accelerating the development of new pharmaceutical, biotechnology, medical device, and diagnostic products is paramount in improving global health.”

“Elligo’s vision to positively impact future generations is something we’re excited to continue to support,” said Allen Moseley, managing general partner at Noro-Moseley Partners.

About Elligo
Elligo Health Research, an integrated research organization (IRO), accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using our novel IntElligo Research Stack™ clinical technology and our Goes Direct® approach. We unite the best clinical experts with the best research infrastructure — creating the ultimate clinical trial solution. It is our mission to ensure that all patients have access to clinical trials as a care option by maintaining the integrity of the trusted patient and physician relationship, and building global communities of research leveraging electronic health records. In doing so, we expand the base of physicians and their patients who otherwise would not participate in clinical trials. Learn more at elligodirect.com.

About Piper Jaffray
Piper Jaffray Companies (NYSE: PJC) is a leading investment bank and asset management firm. Securities brokerage and investment banking services are offered in the U.S. through Piper Jaffray & Co., member SIPC and FINRA; in Europe through Piper Jaffray Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Jaffray Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Asset management products and services are offered through five separate investment advisory affiliates―U.S. Securities and Exchange Commission (SEC) registered Advisory Research, Inc., Piper Jaffray Investment Management LLC, PJC Capital Partners LLC and Piper Jaffray & Co., and Guernsey-based Parallel General Partners Limited, authorized and regulated by the Guernsey Financial Services Commission.

Austin, Jan. 9, 2019 – Elligo Health Research, an integrated research organization, has acquired Protenium Clinical Research. Protenium, an established research group led by Robert Strzinek, Ph.D., D.O., conducts pharmaceutical studies in a broad range of therapeutic areas.

Dr. Strzinek has more than 15 years of clinical research experience and will now conduct research at his practice in partnership with Elligo. The acquisition brings the number of patients in Elligo’s Research Ready network to more than one million. As part of Elligo’s Goes Direct® approach, these patients will now have access to clinical research as a care option from their own trusted physician.

“Joining Elligo’s Dallas–Fort Worth Community of Research will ensure that we continue to provide the best clinical research opportunities to our patients and help us expand research opportunities across the region,” said Dr. Strzinek. “Our partnership allows us to focus on patient care while benefiting from Elligo’s research relationships and operational expertise.”

Dr. Strzinek has completed over 150 research studies and authored numerous journal articles covering several areas including endocrinology and women’s health. He and the Elligo team will continue to conduct research and support other community-based health care providers participating in research.

“The opportunity to leverage Dr. Strzinek’s highly experienced practice and integrated clinical operation in our Research Ready network and Communities of Research furthers our mission to bring together and empower health organizations and improve clinical trial access and efficiency,” said John Potthoff, Ph.D., CEO at Elligo. “We are delighted to welcome him, and his staff and patients to the Elligo family.”

About Elligo
Elligo Health Research, an integrated research organization, expands access to clinical research by bringing together health care data, community physicians and their patients. Only Elligo’s Goes Direct® approach and IntElligo Research Stack™ clinical technology — a complete standards-based technology solution — deliver better patients and improved real-time data through Elligo’s network of Research Ready sites within its Communities of Research. Learn more at elligodirect.com.

Austin, Texas, Sept. 27, 2018 – Elligo Health Research, an integrated research organization, has added Dan Pucci, MBA, as vice president of strategic partnerships, and Michael A. Ibara, Pharm.D., as vice president of data sciences, to its executive leadership team.

Pucci will lead Elligo’s strategic partnerships and new practice development group. Through this group, and in partnership with Elligo’s network management group, Pucci will develop key business relationships that grow and nurture Elligo’s network of Research Ready sites. In this role, he will directly support Elligo’s effort to bring together health care data with community physicians and their patients.

Pucci has a decade of experience building commercial and research partnerships with life sciences and health care insights organizations. Prior to Elligo, he helped develop and grow the point-of-care content, and payer and life sciences business units at Allscripts Healthcare Solutions.

Ibara, who has a record of innovation in the pharmaceutical industry and more than two decades of experience bringing together health care data and digital technologies in regulatory environments, most recently served as head of digital health care for the Clinical Data Interchange Standards Consortium (CDISC).

In his new role, Ibara will support the data sciences team as they apply analytical and algorithmic techniques to clinical data, improving patient matching, trend identification and reporting of insights to patients, investigators and sponsors. Ibara will also lead data-driven research projects for Elligo’s clients and provide subject matter expertise across all aspects of pharmacovigilance.

“Elligo has seen a lot of growth over the last several months,” said John Potthoff, Ph.D., CEO at Elligo. “Both Dan’s and Michael’s experience and respective strengths will keep our team at the forefront of the effort to bring clinical research and clinical care together to improve research study participation and trial quality across the board.”

About Elligo
Elligo Health Research, an integrated research organization, expands access to clinical research by bringing together health care data, community physicians and their patients. Only Elligo’s Goes Direct® approach and IntElligo Research Stack™ clinical technology — a complete standards-based technology solution — deliver better patients and improved real-time data through Elligo’s network of Research Ready sites within its Communities of Research. Learn more at elligodirect.com.

Austin, Texas, and Avon, Conn., August 14, 2018 – Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, announces its partnership with Women’s Health USA, a growing national network of women’s health, obstetrics and gynecology practices. The partnership will expand Elligo’s Research Ready™ network to include Women’s Health USA health care providers, allowing their patients to access clinical research as a care option from their trusted physician.

With more than 600 physician partners practicing in seven states, this partnership will make it easier for Women’s Health USA’s patients to participate in clinical research. “We can make a bigger impact on the future of medicine together,” said Chad Moore, president of Elligo. “With our partners’ help, not only are we bringing clinical research direct to clinical health care, but we are matching more participants to clinical trials than ever before.”

Elligo’s Goes Direct® approach provides physician practices with the infrastructure, technology and expertise necessary to conduct clinical research. “Our goal is to help our women’s health practices leverage the best tools for the best outcomes,” said Goran Dragolovic, CEO at Women’s Health USA. “Partnering with Elligo allows our providers to maintain the highest standards for quality, patient-focused care, while adding innovative, state-of-the-art treatment options for their patients.”

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About Women’s Health USA
Women’s Health USA currently partners with OB/GYN, in vitro fertilization, and other specialty women’s health practices in seven states to implement growth strategies, payer engagement, revenue cycle management, EMR support, financial and human resource management, merger and acquisition support, ancillary services development, marketing and risk management services. With more than 600 physician partners, its unique and successful partnership model enables physicians and physician groups to maintain their independence, while leveraging the resources of a national organization.

Austin, Texas, July 10, 2018 — Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, has appointed former founder, executive chairman and CEO of Greenway Health, Wyche T. “Tee” Green III, as a director. Green has been a force behind the health care information technology (IT) movement since he co-founded Greenway Medical Technologies (now Greenway Health) in 1998.

Bridging the gap between clinical research and physician practices is the focus of Elligo’s approach. Green, who has dedicated nearly two decades to integrating and streamlining clinical, financial, administrative and patient-facing health care information systems, will provide Elligo with invaluable insight. While at Greenway, he invested in bringing clinical trials to thousands of providers and patients with a single mission: to improve health.

“We are honored and excited that Tee Green has accepted our invitation to join the board of directors,” said John Potthoff, Ph.D., CEO of Elligo. “This is a great leap for Elligo. We look forward to working with Tee as we refine our information systems and seek out new ways to make life-changing research accessible to all.”

“I’ve dedicated my career to improving population health by building a smarter, more sustainable health care system with advanced, integrated, information services,” said Green. “Increasing connectivity for the greater good is my passion, so when I realized Elligo was working to connect researchers with patients, I was intrigued.”

In addition to his work in health care IT and health care reform, Green has served on several additional boards ranging from the Auburn University Research Advisory Board to West Georgia Habitat for Humanity.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Austin, Texas, and Arlington, Va., June 26, 2018 – Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, has partnered with HealthiVibe, an organization that gathers patient insights to optimize clinical trials. The goal of the partnership is to bring the patient to the center of the clinical trial experience. Elligo will now offer HealthiVibe’s HealthiPerspectives™ end-to-end patient survey and industry benchmarking platform to its network of sites.

The HealthiPerspectives platform is a first-of-its-kind, sustainable, repeatable and scalable process for leveraging patient feedback during a clinical trial. Through its cloud-based, web survey interface, HealthiPerspectives will gather the patient-sourced data needed by Elligo to make real-time modifications to the way clinical trials are conducted, drawing on quantifiable insights to increase enrollment and retention and deliver more cost-effective studies.

“Partnering with Elligo enables us to continue to expand our offering,” said Jennifer Kelly, vice president at HealthiVibe. “Aligning with Elligo will increase our industry benchmarking database, providing valuable patient insights that will ultimately enhance our mission of making the patient voice an integral part of the clinical trial development process.”

“Elligo’s mission is to provide all patients and physicians with the opportunity to participate in clinical trials,” said Deirdre BeVard, chief development officer of Elligo Health Research. ”We want to optimize that experience for our research sites and their patients. This partnership and the subsequent data will help us continue to improve our offering and the patient experience and ultimately move more products to market faster.”

HealthiPerspectives has been implemented by large and small biopharmaceutical companies in more than 180 studies, spanning more than 30 countries and representing dozens of indications. HealthiPerspectives supports more than 200 different languages accessible from any internet-enabled device.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About HealthiVibe
HealthiVibe offers an evidence-based process for companies to assess patient insights at every stage of the pharmaceutical project lifecycle: from clinical trial design through post-approval activities and research. We offer full-service patient initiatives, with a focus on patient insights and communication, to help biopharmaceutical companies create more patient-centered programs. Learn more at HealthiVibe.com.